Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus

A method of vaccinating a human against a viral infection comprising administering an RSV F vaccine to a human subject to obtain an immune response, wherein the RSV F vaccine comprises:

• (a) an RSV F protein trimer, wherein each RSV F protein of the trimer comprises
• (i) a deletion of one or more amino acids of the fusion domain, wherein said fusion domain corresponds to amino acids 137-146 of the wild-type RSV F protein (SEQ ID NO:
• 2), and
• (ii) an inactivated primary furin cleavage site, wherein the primary furin cleavage site corresponds to amino acids 131-136 of the wild-type RSV F protein (SEQ ID NO:
• 2), wherein the primary furin cleavage site is inactivated by amino acid substitution;
• (b) a pharmaceutically acceptable carrier, and
• (c) an alum adjuvant;
• wherein the immune response comprises antibodies that bind to a palivizumab epitope peptide on the RSV-F protein and wherein the antibodies are produced at a concentration of at least 40 μg/ml by 30 days after administration.

A method of inducing antibodies that bind to a palivizumab epitope peptide on the RSV-F protein in a human, comprising administering to the human intramuscularly an RSV F vaccine, comprising

• (a) an RSV F protein trimer, wherein each RSV F protein of the trimer comprises
• (i) a deletion of one or more amino acids of the fusion domain, wherein said fusion domain corresponds to amino acids 137-146 of the wild-type RSV F protein (SEQ ID NO:
• 2), and
• (ii) an inactivated primary furin cleavage site, wherein the primary furin cleavage site corresponds to amino acids 131-136 of the wild-type RSV F protein (SEQ ID NO:
• 2), wherein the primary furin cleavage site is inactivated by amino acid substitution;
• (b) a pharmaceutically acceptable carrier;
• and
• (c) an alum adjuvant;
• wherein the antibodies are produced at a concentration of at least 40 μg/ml by 30 days after administration.